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26 SYNOPSIS
27 Background/ Objectives
28 Carbapenemase-producing Enterobacteriaceae (CPE) are a public health threat, and have 
29 been found in humans, animals and the environment. Carbapenems are not authorised for use 
30 in EU or UK companion animals, and the prevalence of carbapenem-resistant Gram-negative 
31 bacilli (CRGNB) in this population is unknown. 
32 Methods
33 We investigated CRGNB isolated from animal specimens received by one diagnostic 
34 laboratory from 34 UK veterinary practices (Sept 2015-Dec 2016). Any Gram-negative 
35 isolates from clinical specimens showing reduced susceptibility to fluoroquinolones and/or 
36 aminoglycosides and/or cephalosporins were investigated phenotypically and genotypically 
37 for carbapenemases. A complete genome assembly (Illumina/Nanopore) was generated for 
38 the single isolate identified to investigate the genetic context for carbapenem resistance. 
39 Results
40 One ST410 Escherichia coli isolate [(CARB35); 1/191, 0.5%)], cultured from a wound in a 
41 springer spaniel, harboured a known carbapenem-resistance gene (blaNDM-5).  The gene was 
42 located in the chromosome on an integrated 100kb IncF plasmid, also harbouring other drug 
43 resistance genes (mrx, sul1, ant1, dfrA).  The isolate also contained blaCMY-42 and blaTEM-190 
44 on two separate plasmids (IncI1 and IncFII, respectively), which showed homology with 
45 other publicly available plasmid sequences from Italy and Myanmar.
46 Conclusions
47 Even though the use of carbapenems in companion animals is restricted, the concurrent 
48 presence of blaCMY-42 and other antimicrobial resistance genes could lead to co-selection of 
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49 carbapenemase genes in this population. Further studies investigating the selection and flow 
50 of plasmids carrying important resistance genes amongst humans and companion animals are 
51 needed.
52
53 Introduction
54 Carbapenemase-producing Enterobacteriaceae (CPE) are a serious public health problem due 
55 to limited therapeutic options for CPE-associated infections.1 Increased carbapenem use, 
56 especially for treating infections caused by ESBL-producers, is a significant driver of CPE 
57 emergence in human medicine.2 In contrast, carbapenems are not authorised for veterinary 
58 use3,4 except for the management of MDR Gram-negative infections under the prescribing 
59 cascade 
60 (https://www.gov.uk/guidance/the-cascade-prescribing-unauthorised-medicines#special-
61 considerations-for-the-responsible-use-of-antibiotics-under-the-cascade).
62 Furthermore, there is limited carbapenem resistance testing and no UK national surveillance 
63 of CPE prevalence in companion animals. Consequently, occurrence of carbapenemase-
64 producing bacteria in animals may remain undetected. Here, we report surveillance data from 
65 a UK Veterinary Diagnostics Laboratory which introduced carbapenem-resistance screening 
66 for Gram-negative bacteria. We also describe the molecular characterisation of a NDM-5 
67 producing E. coli isolates isolated from a wound in a dog. 
68
69 Materials and methods
70 Bacterial isolates cultured from clinical specimens submitted September 2015-December 
71 2016 to one UK diagnostic laboratory were included in this study. Clinical specimens were 
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72 received from 34 veterinary practices across England (n=29), Wales (n=4) and Ireland (n=1) 
73 and included swabs, urine, tissues, sterile fluids, bronchoalveolar lavages, faecal samples 
74 (cats, dogs) and bovine milk samples.  To increase detection of all carbapenemase-producing 
75 isolates (including OXA-48 producers), any Gram-negative bacteria with reduced 
76 susceptibility to fluoroquinolones, aminoglycosides and/or cephalosporins cultured were 
77 tested using chromID Carba SMART agar bi-plates (bioMerieux, Basingstoke, UK).
78
79 Each half of the bi-plates was inoculated with 10µl of fresh, pure culture (0.5 MacFarland 
80 suspension), and incubated aerobically (37±2°C, 22-24 hours). Klebsiella pneumoniae 
81 NCTC13368 (SHV-18 [ESBL]) was used as a negative control and K. pneumoniae 
82 NCTC13438 (KPC-3), NCTC13440 (VIM-1) and NCTC13442 (OXA-48) as positive 
83 controls. Isolates exhibiting characteristic growth were identified using either API 
84 (20E/20NE, bioMérieux UK Ltd) or MALDI-TOF (Laboklin, Germany). 
85
86 Susceptibility testing for the carbapenem-resistant isolate identified in this study was 
87 performed by broth microdilution (TREK Diagnostic System, West Sussex, UK), interpreted 
88 according to the European Committee on Antimicrobial Susceptibility testing guidelines 
89 (version v7.0, at: 
90 http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_7.1_B
91 reakpoint_Tables.pdf). 
92
93 Bacterial DNA was extracted by heat lysis and centrifugation, and used to screen for: 
94 carbapenemases (blaNDM, blaOXA-48-like, blaVIM, blaIMP, blaKPC); ESBLs (blaCTX-M, blaTEM, 
95 blaSHV blaGES, blaPER, blaVEB ); plasmid-mediated pAmpC-group genes,5, 6 and colistin 
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96 resistance (blaMCR-1, blaMCR-2; https://www.eurl-ar.eu/CustomerData/Files/Folders/21-
97 protocols/278_mcr-multiplex-pcr-protocol-v2-oct16.pdf) as previously described.
98
99 Whole genome sequencing and analysis
100 The carbapenem-resistant E. coli isolate was re-cultured from stock; DNA was extracted 
101 using the Qiagen Genomic-tip 100/G kit (Qiagen, Hilden, Germany). Aliquots of the same 
102 DNA extract were sequenced on both the Illumina HiSeq 4000 and Oxford Nanopore 
103 Technologies’ MinION (library preparation kit: SQK-LSK208, flowcell: FLO-MIN106 R9.4, 
104 as in Phan HTT et al.7 Sequence data have been deposited in the NCBI (BioProject: 
105 PRJNA473397).
106
107 A hybrid, complete genome assembly was constructed from the two sequencing datasets 
108 using Unicycler (v4.1; parameters: --no_correct --min_component_size 500 --
109 min_dead_end_size 500 --verbosity 1 --mode bold). The Unicycler assembly was also 
110 compared with a hybridSPAdes (v.3.6; default parameters, “careful” option) assembly to 
111 verify the genome structure using a different assembly method. 
112
113 In silico MLST typing was performed using BLASTn against the PubMLST allele databases 
114 (available at https://pubmlst.org/general.shtml). Plasmid typing, insertion sequence typing 
115 and resistance gene characterisation were carried out using PlasmidFinder, the ISFinder 
116 database and an in-house script (ResistType), as previously described.7 The chromosomally 
117 integrated plasmid sequence and multi-drug resistance region harbouring blaNDM-5 were 
118 compared with publicly available plasmid sequences in GenBank using BLASTn, with 
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119 default settings. Data visualisations were created using the GenomeDiagram module in 
120 Biopython. 
121
122 Results
123 One hundred and ninety-one Gram-negative isolates from dogs (n=158), cats (n=27), cattle 
124 (n=4), a rabbit and a guinea pig, were sub-cultured onto chromID Carba SMART bi-plates; of 
125 these, 28 isolates generated moderate-heavy growth, where Acinetobacter spp. (n=4) and 
126 Pseudomonas spp. (n=23) grew on one or both halves, whilst Escherichia coli (1/191) grew 
127 on the CARB side only.
128
129 No blaESBL/pAmpC or carbapenem-resistance genes were identified in cultured Pseudomonas 
130 spp. and Acinetobacter spp. which were most likely selected due to their intrinsic resistance 
131 (decreased permeability and/or expression of efflux pumps) to the agents included in the 
132 CARBA-SMART plates. However, the E. coli isolate (isolate CARB35) harbored blaNDM 
133 (confirmed on sequencing to be blaNDM-5), blaCMY and blaTEM, The NDM-producing E. coli 
134 was cultured (pure growth) from a foreleg wound on the 5th digit of a 7-year-old English 
135 springer spaniel. The dog had a history of foot lacerations, dog bite wounds and urinary tract 
136 infections, for which he received multiple courses of amoxicillin/clavulanate, cefovecin, 
137 doxycycline and enrofloxacin in the preceding six years. 
138
139 The NDM-producing E. coli was resistant to ampicillin, cefoxitin, aztreonam, cefazolin, 
140 cefepime, cefpodoxime (all >16µg/mL), amoxicillin/clavulanate (>32 µg/mL), 
141 piperacillin/tazobactam, ticarcillin/clavulanate (>64 µg/mL), meropenem, imipenem 
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142 (4µg/mL), ciprofloxacin(2µg/mL), levofloxacin (>8 µg/mL), and 
143 trimethoprim/sulfamethoxazole (>4 µg/mL). The isolate remained susceptible to gentamicin, 
144 amikacin (≤1 and ≤4 µg/mL, respectively), tigecycline (≤0.25 µg/mL), and 
145 colistin/polymyxin B (≤0.25 µg/mL). 
146
147 The two assemblers agreed on a complete assembly for the NDM-5-producing E. coli isolate 
148 which included a chromosome (~4.9Mb; ST410) and five plasmids (~3kb, 4kb, 59kb [IncI1], 
149 89kb [IncFII], 90kb [IncY). blaNDM-5 was chromosomally integrated into the E. coli genome, 
150 flanked by multiple IS elements, in an 18.6kb configuration harbouring other drug resistance 
151 genes (mrx, sul1, ant1, dfrA) (Fig.1). A similar flanking sequence for blaNDM-5 has been 
152 observed in only a handful of publicly available but largely unpublished sequences, including 
153 submissions from the US, China and Germany (Fig.S1). This multi-drug resistance region 
154 was nested within a 100kb region encoding plasmid-associated genes, including IncFII, 
155 IncFIA and IncFIB replicons, and flanked by two IS150 insertion sequences in the same 
156 orientation, most consistent with it representing an integrated plasmid (Fig. 1).  This 100kb 
157 region had 99% sequence identity over 86% of its length to the reference plasmid sequences 
158 CP024860.1 (172kb; submitted Nov-2017 by NIH, USA; isolation source unknown) and 
159 KP789020.1 (E. coli WCHEC13-8 plasmid pCTXM15 harbouring blaNDM-1 and blaCMY-42 
160 from Chengdu, China; 56kb; submitted Nov-2015; human clinical isolate). 
161
162 The IncI1 plasmid (59kb), carrying blaCMY-42, had a 99% sequence match to E.coli plasmid 
163 tig00001287_pilon (GenBank accession: CP021882.1, 68kb);the IncFII plasmid (89kb), 
164 carrying blaTEM-190, shared 99% sequence identity over 93% of the sequence query with two 
165 E.coli plasmids (GenBank accessions: KY463220.1, AP018147.1). 
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166
167 Genes/gene mutations encoding resistance to spectinomycin/streptomycin (aadA2 - 
168 chromosome, positions: 194104-194895), trimethoprim/trimethoprim-sulfamethoxazole 
169 (dfrA12 - chromosome, positions: 193199-193696; sul1 - chromosome, positions: 195400-
170 196239; folP - chromosome, positions: 680079-680927), macrolides-lincosamide-
171 streptogramin (mphA - choromosome, positions: 202749-203654 and plasmid pCARB35-2, 
172 positions: 83836-84741), nitrofurantoin (in nfsA: chromosome, positions: 3510946-3511599) 
173 and fluoroquinolones (gyrA - chromosome, positions: 1676727-1679354; parC - 
174 chromosome, positions: 841664-843922; parE - chromosome, positions: 831111-833003 ), 
175 and fimE (chromosome, positions: 4197047-4197643) and usp (chromosome, positions: 
176 2077529-2077957, 2620969-2621403, and 3475153-3475581) virulence factors, were also 
177 identified. 
178
179 Discussion
180 ESBL/AmpC-producing Enterobacteriaceae have emerged in food-producing and companion 
181 animals over the past two decades.8 Although still rare, carbapenemase-producers, mainly 
182 NDM-1 Acinetobacter spp., VIM-1 E. coli and Salmonella spp., have been reported 
183 worldwide in livestock.9 However, there are very few reports of CPE in companion animals. 
184 NDM-1-producing E. coli was first described in dogs and cats from the US in 2013, only four 
185 years after the first description of NDM-1-producing bacteria in humans.10 OXA-48-
186 producing E. coli and Klebsiella spp. were first reported in dogs from Germany and 
187 subsequently also in clinical canine isolates in the US, including pandemic strains such as E. 
188 coli ST648.11, 12 However, a low prevalence (0.6%, n=160) of CPE, consisting of a single 
189 VIM-1-producing K. pneumoniae isolate, was found amongst companion animals from 
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190 Spain.13 More recently, IMP-4-producing Salmonella Typhimurium was isolated from a cat 
191 with persistent haemorrhagic diarrhoea in Australia14 and OXA-23-producing A. baumannii 
192 associated with urinary tract infection was detected in a cat from Portugal.15
193
194 NDM-5 differs from NDM-1 by two amino acid substitutions and has been described in 
195 Enterobacteriaceae from both humans and livestock, mainly in Asian countries, including 
196 Myanmar.16 NDM-5-producing E. coli was also recently reported in clinical isolates from 
197 Italian patients, one of which had a history of travel to Thailand,17 and also in Spain in a 
198 patient who had not travelled abroad.18 In companion animals, NDM-5-producing E. coli 
199 ST1284 was isolated form a rectal swab in a dog from Algeria; molecular characterisation 
200 suggested that blaNDM-5 was likely to be chromosomally located.19
201
202 The NDM-5-producing E. coli isolate in our study was ST410, and harboured blaNDM-5 on a 
203 plasmid integrated into the chromosome. ST410 is an emerging clone with worldwide 
204 distribution, associated with MDR human infections, including bloodstream infections and 
205 demonstrating potential for nosocomial spread.20 blaTEM-190 was present on an IncFII plasmid 
206 highly similar to IncFII blaNDM-5 plasmids found in human clinical isolates from Italy (ST405) 
207 and Myanmar (ST410).16, 18 Our isolate also harboured blaCMY-42 located on an IncI1 plasmid, 
208 similarly present in the Italian NDM-5 producing E. coli isolates,17 suggesting a shared 
209 plasmid population amongst which blaNDM-5, blaTEM-190 and blaCMY-42 are circulating. 
210
211 Although blaNDM-1 is common amongst human carbapenem-resistant isolates in the UK, 
212 blaNDM-5 has been reported on only a small number of occasions: once, in 2011, also on an 
213 IncFII plasmid in a ST648 E. coli recovered from a patient recently hospitalised in India,21 
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214 and in 2014, in four  ST410 isolates, for which there are limited additional metadata, and in 
215 which the genetic location of blaNDM-5 could not be determined.20 Given the similarity of its 
216 genetic background with previously described human isolates, the low prevalence of CPE in 
217 animals, and the increasing evidence of environmental contamination with CPE by human 
218 hospital effluents,8 it is possible that the NDM-5-E. coli isolated in this study might be of 
219 human origin. Our study was limited with respect to the sampling frame and lack of available 
220 epidemiological data, but suggests that further detailed studies on the selection and flow of 
221 important resistance genes, including carbapenemases, amongst humans and animals are 
222 needed. 
223
224 Although the use of carbapenems in companion animals is uncommon, the concurrent 
225 presence of blaCMY-42 and blaTEM-190 on common plasmids could lead to rapid co-selection of 
226 blaNDM in this population. In addition, the detection of a carbapenemase producing E. coli 
227 ST410 recently described as a high-risk MDR clone with increased potential for inter-species 
228 transmission,22 in companion animals is concerning. Hence, improved antimicrobial 
229 stewardship as well as introducing routine detection of carbapenem-resistance in animal 
230 isolates is warranted to reduce the risk of zoonotic transmission and will contribute to 
231 concerted “One Health” efforts in containing the spread of resistance to last resort 
232 antimicrobials.   
233
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348 Fig 1: Genomic structure of Escherichia coli CARB35, with the blaNDM-5-containing plasmid-
349 like structure integrated into the chromosomal sequence. Insets show the structures flanking 
350 the blaNDM-5 gene in greater detail, highlighting the presence of multiple other co-localised 
351 drug resistance genes and insertion sequences (This figure appears in colour in the online 
352 version of JAC and in black and white in the printed version of JAC)
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355 Fig S1. Blastn alignments to multi-drug-resistance region of pCARB35-1 (last accessed: 10/Aug/2018) (last accessed: 10/Aug/2018) 
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Fig S1. Blastn alignments to multi-drug-resistance region of pCARB35-1 (last accessed: 10/Aug/2018) (This figure appears in colour in the 
online version of JAC and in black and white in the printed version of JAC)
GenBank accession
CP023871.1
CP023923.1
CP027703.1
CP030329.1
CP025626.1
CP024805.1
CP029978.1
MG649062.1
CP026201.1
CP023895.1
GenBank Strain Chromosome/Plasmid Species Country Source
accession
CP023871.1 FDAARGOS_434 Plasmid E. coli Unknown
(unpublished)
CP023923.1 FDAARGOS_440 Plasmid K. Unknown
pneumoniae (unpublished)
CP027703.1 675SK2 Plasmid E. coli Switzerland Wastewater
CP030329.1 AR_452 Plasmid E. coli Unknown
(unpublished)
CP025626.1 SCEC020007 Plasmid E. coli Unknown
(unpublished)
CP024805.1 AMA1167 Plasmid E. coli Unknown
(unpublished)
CP029978.1 51008369SK1 Plasmid E. coli Unknown
(unpublished)
MG649062.1 Ec001 Plasmid E. coli Italy Urine, human
PMID: 29501819
CP026201.1 ECONIH6 Plasmid E. coli USA Unknown
(unpublished)
CP023895.1 FDAARGOS_433 Plasmid E. coli Unknown
(unpublished)
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